BioSpace News Archive

Pliant Therapeutics, Inc. announced two poster presentations, including a late-breaker, at the upcoming European Association for the Study of the Liver International Liver Congress™ taking place in Milan, Italy from June 5-8, 2024.

Nuvectis Pharma, Inc. reported its financial results for the first quarter 2024 and provided an update on recent business progress.

Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced financial results for the three months ended March 31, 2024 and highlighted recent corporate updates.

CalciMedica Inc. announced the acceptance of an abstract for poster presentation by a collaborator from Cedars-Sinai Medical Center at the upcoming Digestive Disease Week 2024 being held May 18-21 in Washington, DC and virtually.

Insmed Incorporated, a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, announced that management will present in a fireside chat at the BofA Securities Health Care Conference 2024 in Las Vegas, NV, on Tuesday, May 14, 2024 at 2:20 p.m. PT.

Sciwind Biosciences Co., Ltd. and HK inno.N Corporation announced a licensing and partnership agreement for the development and commercialization of ecnoglutide injection, a novel GLP-1 analog for the treatment of type 2 diabetes, obesity and MASH, in South Korea.

eyeDNA Therapeutics, a newly created subsidiary of Coave Therapeutics, a genetic medicine company focused on developing life-changing therapies, announces positive 24-month follow-up results from its Phase I/II study evaluating the safety and efficacy of HORA-PDE6b, its investigational gene therapy for retinitis pigmentosa caused by bi-allelic mutations in the PDE6b gene.

Fractyl Health, Inc. announced it will report financial results for the first quarter 2024 and provide business updates after market close on Monday, May 13, 2024.

Aurinia Pharmaceuticals Inc. announced that it will attend the 2024 RBC Capital Markets Global Healthcare Conference in New York from May 14-15, 2024.

Connect Biopharma Holdings Limited announced data from its global Phase 2b trial of rademikibart in patients with moderate-to-severe asthma was accepted as a late-breaking abstract for poster presentation at the upcoming ATS 2024 International Meeting being held May 17-22, 2024 in San Diego, CA.